Direct‐acting antivirals are effective and safe in HCV/HIV‐coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

Direct‐acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV‐coinfected patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2018-10, Vol.18 (10), p.2513-2522
Hauptverfasser:	Castells, LLuís, Testillano, Milagros, Moreno, Ana, Luisa González‐Diéguez, María, Calvo‐Pulido, Jorge, Cuervas‐Mons, Valentin, Manuel Sousa, José, Jiménez, Miguel, Fernandez, José R., Esteban‐Mur, Juan I., Crespo, Gonzalo, Castro, M.A., Agüero, F., Blanch, J., Brunet, M., Cervera, C., Lazzari, E., Forner, A., Fuster, J., Forns, X., Laguno, M., Lligoña, A., Mallolas, J., Murillas, J., Paredes, D., Pérez, I., Torres, F., Tural, C., Tuset, M., Losada, E., Molina, E., Otero, E., Varo, E., Araiz, J.J, Barrao, E., Larraga, J., Lozano, R., Luque, P., Sanjoaquín, I., Tejero, E., Clemente, G., Cosín, J., García‐Sabrido, J.L., Gutiérrez, I., López, J.C., Miralles, P., Cruz, J., Fernández, J.L., Santoyo, J., Alonso, M.P., Rafecas, A., Fabregat, J., Jorba, R., Lladó, L., Montejo, M., Bustamante, J., Fernández, J.R., González, J., Montejo, E., Ruiz, P., Suárez, M.J., Ventoso, A., Abradelo, M., Costa, J.R., García‐Sesma, A., Jiménez, C., Meneu, J.C., Moreno, E., Olivares, S.P., Pulido, F., Blanes, M., López, R., Prieto, M., Fariñas, M.C., Casafont, F., Echevarria, S., Gomez‐Fleitas, M., Herrera‐Noreña, J.L., Moreno, S., Moreno, A.M., Torre‐Cisneros, J., Briceño, J., Mata, M., Rivero, A., Rufian, S., García Pajares, F., Bachiller, P., Almohalla, C., Barrera, A., Charco, R., Gavaldá, J., Ribera, E., Vargas, V., Pons, J.A., Cordero, E., Bernal, C., Suárez, G., Moyano, B., Mahillo, B., Samuel, D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs CD4 antigen clinical research/practice Cohort analysis Coinfection - drug therapy Coinfection - virology Drug Therapy, Combination Female Fibrosis Follow-Up Studies Genotypes Health risk assessment Hepacivirus - drug effects Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology HIV HIV - drug effects HIV Infections - drug therapy HIV Infections - virology Human immunodeficiency virus Humans infection and infectious agents—viral: hepatitis C infection and infectious agents—viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) Infections Interferon Liver Liver transplantation Liver Transplantation - methods liver transplantation/hepatology Liver transplants Lymphocytes T Male Middle Aged Patients Prognosis Prospective Studies Recurrence Ribavirin Ribonucleic acid RNA Transplant Recipients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Direct‐acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV‐coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV‐coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV‐monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV‐coinfected patients had a median (IQR) CD4 T‐cell count of 366 (256‐467) cells/µL. HIV‐RNA was
ISSN:	1600-6135 1600-6143
DOI:	10.1111/ajt.14996